Casirivimab+imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
LANDRAY M. et al, (2021), The Lancet
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
Horby PW. et al, (2021), Lancet Respiratory Medicine, 9, 1419 - 1426
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
LANDRAY M. et al, (2021), The Lancet
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.
Working paper
Horby P. et al, (2021), Lancet, 398
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
Journal article
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group None. et al, (2021), JAMA
Making trials part of good clinical care: lessons from the RECOVERY trial.
Journal article
Pessoa-Amorim G. et al, (2021), Future Healthc J, 8, e243 - e250
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
RECOVERY Collaborative Group None. et al, (2021)
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
RECOVERY Collaborative Group None. et al, (2021)
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Working paper
RECOVERY Collaborative Group None., (2021), Lancet
Realising the full potential of data-enabled trials in the UK: a call for action
Journal article
LANDRAY M. et al, (2021), BMJ Open
Realising the full potential of data-enabled trials in the UK: a call for action
Journal article
LANDRAY M. et al, (2021), BMJ Open
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2021), Lancet, 397, 1637 - 1645
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
LANDRAY M. et al, (2021), The Lancet
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
The RECOVERY Collaborative Group None. et al, (2021)
Author Correction: Potential health and economic impacts of dexamethasone treatment for patients with COVID-19.
Journal article
Águas R. et al, (2021), Nat Commun, 12
Hydroxychloroquine in Hospitalized Patients with Covid-19. Reply.
Journal article
Horby P. et al, (2021), N Engl J Med, 384
Dexamethasone in Hospitalized Patients with Covid-19.
Journal article
RECOVERY Collaborative Group None. et al, (2021), N Engl J Med, 384, 693 - 704
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Journal article
RECOVERY Collaborative Group None. et al, (2021)